The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): Biomarker analysis of the NeoPACT trial.
 
Shane R Stecklein
Research Funding - Natera
 
Rachel Yoder
No Relationships to Disclose
 
Joshua M. Staley
No Relationships to Disclose
 
Zachary Schmitt
No Relationships to Disclose
 
Anne O'Dea
Honoraria - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Pfizer; Puma Biotechnology
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Novartis; Pfizer; Puma Biotechnology; Seagen; Stemline Therapeutics
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Pfizer; Puma Biotechnology
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Pfizer; Puma Biotechnology
 
Lauren Elizabeth Nye
Consulting or Advisory Role - bioTheranostics; Myriad Genetic Laboratories
Travel, Accommodations, Expenses - Ambry Genetics
 
Manana Elia
No Relationships to Disclose
 
Deepti Satelli
No Relationships to Disclose
 
Gregory James Crane
No Relationships to Disclose
 
Rashna Madan
No Relationships to Disclose
 
Maura F. O'Neil
No Relationships to Disclose
 
Andrew K. Godwin
Stock and Other Ownership Interests - Clara Biotech
Honoraria - Sinochips Kansas
Consulting or Advisory Role - Biovica
Research Funding - BioFluidica (Inst); Clara Biotech (Inst); Predicine (Inst); VITRAC Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Provisional Patent application entitled - "WJMSC-Derived Small Extracellular Vesicle (sEVs) Enhance T Cell Suppression Through Checkpoint PD-L1" - Dr. Joseph McGuirk (applicant) (Inst)
 
Roberto Salgado
Consulting or Advisory Role - AstraZeneca; BMS; Roche
Speakers' Bureau - Exact Sciences
Research Funding - Merck; Puma Biotechnology; Roche
Travel, Accommodations, Expenses - Merck; Roche
 
Qamar J. Khan
No Relationships to Disclose
 
Joyce O'Shaughnessy
Honoraria - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; G1 Therapeutics; Genentech; Gilead Sciences; GRAIL; Halozyme; HERON; Immunomedics; Ipsen; Lilly; Merck; Myriad Pharmaceuticals; Nektar; Novartis; Ontada/McKesson; Pfizer; Pharmacyclics; Pierre Fabre; Prime Oncology; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax; Synthon; Taiho Oncology; Takeda
Consulting or Advisory Role - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; G1 Therapeutics; Genentech; Gilead Sciences; GRAIL; Halozyme; HERON; Immunomedics; Ipsen; Lilly; Merck; Myriad Pharmaceuticals; Nektar; Novartis; Ontada/McKesson; Pfizer; Pharmacyclics; Pierre Fabre; Prime Oncology; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax; Synthon; Taiho Oncology; Takeda
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer; Seagen
Research Funding - Seagen (Inst)
Travel, Accommodations, Expenses - Abbvie; Agendia; Amgen; AstraZeneca; Celgene; Eisai; GRAIL; Ipsen; Lilly; Myriad Pharmaceuticals; Novartis; Pfizer; Puma Biotechnology; Roche; Sanofi; Seagen
 
Priyanka Sharma
Stock and Other Ownership Interests - Amgen Astellas BioPharma (I)
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; GlaxoSmithKline; Merck; Novartis; Pfizer; Sanofi
Research Funding - Bristol-Myers Squibb (Inst); Gilead Sciences; Merck (Inst); Novartis; Novartis (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate